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Abstract
The functions of key oncogenic transcription factors independent of context have not been fully delineated despite our
richer understanding of the genetic alterations in human cancers. The MYC oncogene, which produces the Myc
transcription factor, is frequently altered in human cancer and is a major regulatory hub for many cancers. In this regard, we
sought to unravel the primordial signature of Myc function by using high-throughput genomic approaches to identify the
cell-type independent core Myc target gene signature. Using a model of human B lymphoma cells bearing inducible MYC,
we identified a stringent set of direct Myc target genes via chromatin immunoprecipitation (ChIP), global nuclear run-on
assay, and changes in mRNA levels. We also identified direct Myc targets in human embryonic stem cells (ESCs). We further
document that a Myc core signature (MCS) set of target genes is shared in mouse and human ESCs as well as in four other
human cancer cell types. Remarkably, the expression of the MCS correlates with MYC expression in a cell-type independent
manner across 8,129 microarray samples, which include 312 cell and tissue types. Furthermore, the expression of the MCS is
elevated in vivo in Em-Myc transgenic murine lymphoma cells as compared with premalignant or normal B lymphocytes.
Expression of the MCS in human B cell lymphomas, acute leukemia, lung cancers or Ewing sarcomas has the highest
correlation with MYC expression. Annotation of this gene signature reveals Myc’s primordial function in RNA processing,
ribosome biogenesis and biomass accumulation as its key roles in cancer and stem cells.
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Introduction
Key oncogenic pathways are being revealed through sequencing
of the human cancer genomes. While genetic alterations in specific
human cancers continue to accumulate through deep sequencing,
whether key oncogenic hubs, such as the MYC oncogene, behave
in a general way or in a context dependent manner remains poorly
understood. For that matter, whether alterations in oncogenic
transcription factors result in cell-type independent effects has not
been fully appreciated. In this regard, we focus on the MYC
oncogene, which produces the Myc transcription factor involved
in no less than 50% of human cancers, and seek to identify a
putative cell-type independent target gene signature that might
reveal Myc’s primordial function in metazoans.
The c-myc (MYC) proto-oncogene was discovered over two
decades ago as the cellular homolog of the retroviral v-myc gene
that is sufficient to cause a variety of tumors in chickens [1,2].
Deregulated expression of human MYC by multiple mechanisms
contributes to human malignancies. Indeed, MYC is the most
frequently amplified human oncogene and its activation by
chromosomal translocation is a hallmark of Burkitt lymphoma
[3]. Although MYC belongs to a family of related genes, including
MYCN and MYCL, MYC is the most frequently activated member
in human cancers. MYCN is well-known to be amplified in Stage
IV neuroblastoma, and children with highly amplified MYCN
suffer aggressive, poor prognosis disease [4].
In the mouse, homozygous deletion of c-Myc results in
embryonic lethality, and conditional loss of c-Myc leads to tissue
specific dysfunctional stem cell or committed progenitor compart-
ments [5]. Mouse skin stem cells require c-Myc for differentiation
into keratinocytes [6], and c-Myc is necessary for T lymphocyte
progenitors to commit toward mature T cell compartments [7].
Hence, in tissue-specific stem cells c-Myc directs early rounds of
cellular proliferation preceding terminal differentiation required
for generating functional cell types. Ectopic MYC expression in
normal cells, particularly lymphocytes, results in the activation of
checkpoints, such as p53, Arf or BimL, which cause apoptosis
and/or cell cycle arrest [8,9]. Furthermore, enforced Myc
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tion associated with apoptosis of the targeted tissue, and frank
tumors arise following loss-of-function mutations in these check-
points.
Intriguingly, Myc belongs to a cast of four transcription factors,
including Sox2, Oct4 and Klf4, which together are sufficient to
induce pluripotent stem cells (iPSCs) from somatic cells [10]. The
iPSCs behave nearly identically to embryonic stem cells (ESCs),
and removing Myc from this cocktail drastically reduces the
efficiency of the induction of pluripotency [11]. Although MYC
activates miRNAs that suppress mESC differentiation, the roles of
MYC in establishing and maintaining pluripotency remain poorly
understood [12,13]. It is notable that ESC proliferation rates are
faster than those of somatic cells, with mouse ESCs (mESCs)
doubling as fast as every 5 hours and human ESCs (hESCs) do so
every 16 hours [14,15]. The cell cycles of both mESCs and hESCs
have shortened G1 phases [15], in which ribosome biogenesis
contributes significantly to the acquisition of a critical cell size for
S-phase entry [16].
Myc associates with its partner, Max, forms a heterodimer, and
regulates transcription by binding to canonical or related Myc
consensus binding sites, with a preference for E-boxes having the
sequence 59-CACG/ATG-39 [2,17,18,19]. Upon binding, Myc-
Max recruits cofactors that activate transcription largely through
release of transcriptional pause [20]. Our previous mapping of
Myc target sequences by chromatin immunoprecipitation and
paired-end tag (ChIP-PET) sequencing revealed almost 3000 high
quality binding sites, and predicted an estimated total of 6000
functional sites in the human model B cell genome [21]. Here we
report, for the first time, Myc binding sites in hESCs. Due to
unsaturated sequencing of our previous ChIP-PET library, we re-
mapped Myc binding sites in human promoters in the P493-6 B
cell. We have also measured genes that respond to MYC activation
in P493-6 B cells by measuring both transcriptional rates using
genome-wide nuclear run-on and steady-state RNA levels using
microarray analyses of total RNA [22]. In addition, we have
compared our MYC target genes with MYC targets in three
cancer cell lines identified by ENCODE ChIP-seq data.
Collectively, these analyses revealed a core set of direct Myc
target genes that are shared in P493-6 B cells and in hESCs and
mESCs, as well as in the human tumor HeLa, K562, and HepG2
cells. Importantly, analysis of MYC and this core target gene set in
8129 microarray samples from 312 different cell types showed a
strong correlation between MYC expression and expression of its
core target gene set in spite of the heterogeneity of samples.
Gene ontology analysis further revealed that the core Myc
target genes are enriched with genes involved in ribosomal
biogenesis, nucleolar function, and RNA processing. This Myc
core signature is conserved from Drosophila to man and reveals a
primordial function of MYC involving ribosomal biogenesis,
consistent with both the nucleolar hypertrophy observed in ESCs
and cancer [23,24,25] and with small cell and body sizes of adult
Drosophila diminutive mutant flies having hypomorphic dMyc alleles
that phenocopy loss of ribosomal protein function in Drosophila
[26]. Although Myc’s regulation of ribosomal biogenesis has been
implicated in a few specific biological settings in previous studies
[27,28,29,30], our comprehensive unbiased analysis of data from
many cell types in two species firmly establishes this role of Myc to
be cell type and species independent. Moreover, for the first time,
our analysis identifies this role of Myc in embryonic stem cells,
multiple known MYC-driven cancers, and particularly in other
previously un-suspected cancers. Our analysis of 8129 gene
expression samples suggests that the 51 stringently defined cell
type and species independent MYC core target genes can provide
a signature for future screening of MYC pathway activities in
diverse cell types and diseases.
Results
Identification of the Myc target gene signature and cell
type-specific target genes
To identify a species and cell type independent core set of Myc
target genes we rigorously re-defined Myc target genes in the
P493-6 human B cell model of Burkitt lymphoma containing an
inducible MYC transgene [31,32]. With the ability to regulate Myc
expression level, we identified Myc targets by chromatin
immunoprecipitation (ChIP) using a promoter array (ChIP-chip),
global array-based nuclear run-on assay (ANRO) to measure
changes in transcriptional rates [22], and multiple biological
replicates for gene expression changes upon Myc induction. Genes
that are bound by Myc, responded transcriptionally, and that had
significant changes in total mRNA levels are considered direct
Myc responsive target genes. With this target gene set in hand, we
then identified Myc targets in the human embryonic stem cell line
H9 by ChIP-chip and gene expression changes as discussed below.
The overall strategy to derive a core set of Myc target genes
independent of cell type and species that we designate the Myc
Core Signature (MCS), and to identify cell-type specific Myc target
genes is depicted in Figure 1 (see Table S1 for data sets
analyzed, Table S2 for complete expression and binding analysis,
Table S3 for the MCS and cell type specific target lists, and
Methods S1 for detailed data analysis procedures).
Identification of direct MYC target genes in a human B
cell model of Burkitt lymphoma
We combined data derived from Myc ChIP with promoter tiled
arrays, genome-wide array-based nuclear run-on to identify
transcriptionally regulated genes, and changes in total mRNA
levels to rigorously define direct Myc target genes and to exclude
those whose expression might be altered at a post-transcription
level. To determine the direct binding targets of Myc, ChIP was
performed using two different anti-Myc antibodies in human
P493-6 B cells, a model of Burkitt lymphoma that have an Epstein-
Barr virus genome and a tetracycline (tet)-repressible human MYC
transgene. Following removal of tet, Myc protein is highly induced
and resting P493-6 cells are recruited into the active cell cycle [31].
Purified ChIP DNA from cells with high Myc levels was amplified
and hybridized to Affymetrix human promoter 1.0R arrays.
Signals from both Myc IP and IgG controls were normalized, and
binding regions were detected and visualized using CisGenome
[33]. In these B cells, the Santa Cruz (SC) anti-N-terminal Myc
antibody revealed Myc binding to 2357 regions within 2500 genes
with a false discovery rate (FDR) of 6.75%, while the Epitomics
(Epit) monoclonal anti-N-terminal Myc antibody revealed 2303
bound regions within 2377 genes (FDR=6.82%). Intersection of
these two data sets revealed that Myc binds to the same regions in
1327 genes with two different anti-Myc antibodies (Figure 2).
We previously observed that Myc binding is often insufficient to
trigger a change in gene expression, as only about 700 of the
3000 Myc bound genes identified by ChIP-PET had altered
(induced or repressed) mRNA levels following Myc induction [21].
The same phenomenon was observed in Myc bound targets in
mESCs, where genes that change in expression as a function of
pluripotency have multiple bound transcription factors, such as
Sox2, Oct4, Nanog, and Klf4 along with Myc [34]. As such, we
coupled Myc target site identification by ChIP-chip on tiled
promoter arrays with transcriptional changes using our global
nuclear run-on studies of P493-6 B cells in the presence and
Myc Core Target Gene Signature
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Myc-bound, transcriptionally regulated genes to the set of genes
whose total RNA levels changed (as determined by both standard
expression and exon microarrays) with Myc induction for overlaps.
Combining these three methods identifies, for the first time, a
stringent set of direct Myc responsive genes in human B cells
(Figure 1). The overlap reveals a set of 634 genes, 445 of which
are induced by MYC (Figure 2 and Table S3). Gene ontology
analysis using EASE [35] reveals that genes involved in RNA
binding and processing as well as ribosome biogenesis are some of
the functional classes that are over-represented in this set of Myc
targets (Figure 2).
Identification of a shared signature of MYC bound target
genes in human B cells and embryonic stem cells
MYC plays essential roles in stem cell pluripotency and self
renewal, and in reprogramming adult cells to an induced
pluripotent state [36]. However, the mechanisms by which Myc
directs the induction of pluripotency are poorly understood. To
define MYC’s functional role in ESCs, we determined direct Myc
transcriptional targets in these cells. In hESCs, Myc levels are high
and decrease with differentiation. Embryoid body formation
promotes differentiation of stem cells into all three germ layers
and is an attractive model to study the multipotentiality of hESC,
but this is inherently limited by the cellular heterogeneity [37]. We
therefore chose a simple, robust model that drives a more
homogenous differentiation program, specifically using the bone
morphogenetic protein BMP4 that induces differentiation of
hESCs to trophoblasts, the cells that comprise the placenta [38].
After 6 days of exposure to BMP4, greater than 80% of cells
differentiate and MYC mRNA and protein levels dropped several
fold (Figures 3B and 3C), allowing us to study the Myc
responsive transcriptome in a more uniform cell population.
BMP4-treated H9 hESCs acquired a cobblestone appearance
characteristic of differentiated trophoblasts (Figure 3A), and
expressed high levels of CGA, GATA2 and KRT7 and reduced
levels of pluripotency markers. Flow cytometric analyses revealed
.90% of cells expressed high KRT7 levels compared to untreated
H9 ESCs (Figure 3B).
To measure global gene expression changes associated with
MYC, we isolated total RNA from H9 ESCs treated for 0 or 6 days
with BMP4 and hybridized labeled cDNA to human gene
expression arrays. We validated by qPCR the expression of the
pluripotency markers OCT4 (POU5F1) and NANOG as well as
genes highly expressed in trophoblasts such as GATA2, CGA and
KRT7 that are virtually absent in undifferentiated H9 cells
(Figure 3C). A subset of genes differentially expressed in
undifferentiated hESCs versus trophoblasts should contain Myc
target genes, where Myc-induced hESC target genes should be
down-regulated following differentiation.
To identify potential Myc direct target genes in hESCs, we
performed ChIP-chip in H9 hESCs using one of the anti-Myc
antibodies (Santa Cruz) and identified 1787 binding regions within
1984 genes (FDR=7.16%). The intersection of these Myc-bound
Figure 1. Schema of the strategy to identify the MYC core target gene signature.
doi:10.1371/journal.pone.0026057.g001
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direct targets in B cells reveals a common set of 80 up-regulated
genes (Figure 4A and Table S3). We selected 11 genes from this
set for qPCR validation and in all cases found significant binding
to these promoters by Myc (Figure 4B). An example of the
expression and Myc ChIP-chip data for the target gene fibrillarin
(FBL) common to P493-6 B cells and H9 hESC are shown in
Figure 5. Gene ontology analysis using EASE [35] reveals that
the set of 80 core up-regulated human Myc targets contains genes
involved with ribosome and ribonucleoprotein complex biogene-
sis, as well as RNA binding and metabolic processes (Figure 4A).
Identification of a stringent set of cell type and species
independent MYC core target genes
Next, we determined whether these 80 core Myc target genes
are also bound by Myc in well-established human cancer cell lines.
With the ENCODE Consortium data [39] which provide
mapping of Myc binding sites by ChIP and direct sequencing
(ChIP-seq) in three human cancer cell lines, HeLa (cervical
cancer), K562 (chronic myelogenous leukemia) and HepG2 (liver
cancer), we defined a common set of 73 genes among 5 human cell
lines (Table S3). Notably, gene ontology analysis of this 73 gene
set reveals ribosomal biogenesis and RNA processing as the two
top cellular processes involved.
To identify a species-independent set of core MYC target genes,
we assessed MYC binding to these genes using data from previous
studies of Myc binding sites in mouse ESCs (Table S1). We re-
analyzed raw ChIP-chip data from native Myc and in vivo
biotinylated Myc proteins as well as ChIP-sequencing from two
different studies and found that 51 of the 73 up-regulated genes
are also bound in mESCs [34,40]. Note that the Myc target gene
FBL is also bound by Myc in mESC (Figure 5C). Thus, this core
set of target genes that are bound by MYC in five different human
cells lines and in mouse embryonic stem cells represents a cell type
and species independent Myc Core Signature (MCS).
Cell type restricted MYC targets
In addition to delineating the cell type-independent MCS, our
analyses also provided an opportunity to delineate Myc target
genes that are cell-type restricted to the human B P493 cells or
hESCs, the two systems where we have expression data. Overall,
1523 genes are significantly down-regulated in trophoblasts while
1361 increase in expression as compared with undifferentiated
hESCs. Of the genes more highly expressed in undifferentiated
hESCs but that are not upregulated in Myc-expressing P493 cells,
30 are bound by Myc in H9 hESC but not in P493-6 B cells; thus,
these represent direct MYC transcription targets that are specific
to hESC. Two very interesting novel ES specific human Myc
targets are SOX2 and LIN28 which are both important for
maintaining pluripotency and reprogramming (Figures 4 and 5).
For example, significant Myc binding to LIN28 is manifest in
ESCs but not in other cells assessed in Figure 5. EASE analysis
further reveals that genes involved with cell fate, cell-cell signaling,
and signal transduction are statistically overrepresented in this
hESC-specific MYC target gene set (FDR,22%).
To identify a core set of MYC target genes that are restricted to
human B cells, we utilized P493-6 cells. We compared the
transcriptional profile of proliferating cells with that of cells treated
for 48 hr with tetracycline when these cells have very low MYC
levels and are not cycling. Of the 522 expressed genes that are
bound by MYC exclusively in this B cell model 9.6% of Myc
targets were B cell specific, with 21 increasing with high MYC and
29 being repressed (Table S3). An example of a B cell selective
Myc target is BLMH (Figure 5). Enriched in the list of induced B
cell-specific Myc targets are genes involved in cellular organiza-
tion, protein metabolism, mitochondria and generation of
metabolites and energy. Among the direct B cell-specific targets
suppressed by MYC are genes involved in lymphocyte activation,
immune system development, leukocyte differentiation and
hematopoiesis. Thus, MYC appears to maintain P493-6 B cells
in an undifferentiated state by suppressing genes that direct
lymphocyte maturation.
Role of MCS in the human iPS cells, Em-Myc mouse and
human lymphomas
Having identified a core set of Myc target genes shared between
mouse and human pluripotent stem cells and a variety human
cancer cells, the MCS, we sought to determine the behavior of these
genes in human iPS cells. To determine if the MCS is also manifest
in human iPSCs versus precursor fibroblasts, we examined the
expression profiles of these targets using the publically available
Amazonia website (http://amazonia.transcriptome.eu/ [41]) that
annotates gene expression amongst different human cells and cell
lines. Among the 51 core genes, 43 are significantly induced in
iPSCs compared to the normal fibroblast counterparts, suggesting
that these genes are involved in the pluripotent stem cell state
(Figure S1).
Figure 2. Direct Myc target genes in P493-6 B cells defined by
ChIP-chip, array-based nuclear run-on, and gene expression
changes. Venn diagram illustrating Myc bound target genes identified
with Santa Cruz (SC) or Epitomics (Epit) anti-Myc antibodies. Bound
genes whose expression changed are indicated for the overlap between
SC and Epit. Enriched gene ontologies for these genes are shown.
doi:10.1371/journal.pone.0026057.g002
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model of Myc-driven lymphoma. We used the Em-Myc mouse
model from which one can directly compare expression profiles of
wild type versus Myc-expressing B220+ pre-malignant lympho-
cytes and also query differences in gene expression that ensue
following the neoplastic switch to frank lymphoma [42]. Cluster
analysis of expression of the 51 gene (of which we found murine
probe sets for 48 genes) signature amongst wild type, premalignant
Myc and malignant Myc B lymphocytes reveals a distinct
increased expression of the MCS that correlates with the
transformed malignant phenotype (Figure 6A). Further analysis
showed that while 24.9% (6212 out of 24944) of genes on the
microarray had increasing expression levels from wild type to
premalignant Myc to malignant Myc B lymphocytes, 91.7% of the
MCS (44 of the 48 genes) followed this pattern (Figure 6A,
Methods S1), representing a much higher percentage (.3-fold
enrichment). The overall correlation indicates that the MCS
contributes to the malignant state. As predicted from analyses of
P493-6 cells and hESCs, GSEA analysis established that the
‘‘Ribosome Pathway’’ gene set (http://www.broadinstitute.org/
gsea/msigdb/cards/HSA03010_RIBOSOME.html) is also signif-
icantly enriched in premalignant Em-Myc B220
+ B cells compared
to their wild type counterparts (FDR=0.26%, Figure S2).
Finally, when 173 human mature aggressive B lymphoma samples
were used for the clustering of the 51 gene MCS [43], molecular
Burkitt’s lymphoma (mBL) cases have distinctly higher MYC and
MCS expression than the non-mBLcases (Figure 6B). With
unsupervised clustering (Figure S3), all 44 mBL cases grouped
together along with 10 out of 129 non-mBL cases, which have
higher MCS expression. This observation suggests that some non-
mBL cases in this series have higher MYC and MCS expression.
We further sought to determine the significance of the cell type
restricted Myc target genes found in hESCs versus those found
specifically in human P493-6 B lymphocytes. When P493-6 B cell-
Figure 3. Trophoblastic differentiation of H9 hESCs is associated with reduced Myc. (A) Photomicrographs of H9 hESCs following
exposure to BMP4 for the indicated times. Representative images are shown. (B) Flow cytometry of BMP4 treated cells stained for KRT-PE, a marker of
trophoblastic differentiation. Immunoblot at right shows that Myc protein levels are drastically reduced in BMP4-treated H9 cells. Tubulin
immunoblot shows equal loading of samples. (C) Expression of the indicated stem cell genes and those enriched in trophoblasts was determined by
realtime PCR normalized to B-ACTIN.
doi:10.1371/journal.pone.0026057.g003
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expression from wild type, premalignant Myc or malignant Myc B
cells, the vast majority (15 out of 18, or 83.3%) of the B cell specific
Myc-induced genes increased in this transgenic lymphoma model
(Figure 6C) while 73.9% (17 out of 23) repressed genes were
decreased (Figure S4). On the other hand, the hESC-specific
Myc target genes did not provide the same pattern amongst the B
lymphocytes from wild type or Myc transgenic mice, with only 3
(14.3%) out of the 21 positive targets displaying the increasing
pattern (Figure 6D) and 5 (31.3%) out of the 16 repressed targets
displaying the decreasing pattern (Figure S4).
Correlation of the MCS with MYC expression in 8000
microarray samples
To further determine the cell-type independence of the MCS,
we assessed its expression in a collection of 8129 Affymetrix
human U133A microarray samples stored in Gene Expression
Omnibus [44], representing about 312 different cell and tissue
types. We hypothesized that if the core targets are cell type
independent, one should be able to observe a clear correlation
between the gene expression level of the MCS and MYC
expression across this large collection of microarray samples with
different cell types. Intriguingly, we observe a strong and highly
Figure 4. Myc target genes common to P493-6 B cells and H9 human embryonic stem cells. (A) Venn diagram of Myc bound genes in
P493-6 and H9 hES cells with the overlap containing 80 upregulated genes. The ontology of these shared genes is shown. (B) RT-PCR validation of
Myc-bound target genes in P493-6 and H9 cells with anti-Myc or control IgG signals shown. (C) Validation of Myc-bound targets in H9 hESCs by RT-
PCR.
doi:10.1371/journal.pone.0026057.g004
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PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26057Figure 5. Examples of cell type independent, human ES cell and B cell specific Myc targets. (A) Gene expression levels (at log2 scale) of
FBL, LIN28 and BLMH in the absence and presence of Myc induction in P493-6 B cells (measured by Affymetrix Exon arrays and Affymetrix U133 Plus
2.0 arrays), and log2 gene expression fold changes between hESC and trophoblasts (measured by Agilent microarrays) are shown. Error bars
correspond to standard deviations of replicate samples. (B) ChIP-chip binding signals in human P493-6 B cells and H9 ES cells, and ENCODE ChIP-seq
binding signals in three human cancer cell lines. For ChIP-chip, TileMap moving average statistic [62] m was computed for each probe using
normalized log2 probe intensities, and 2
m was displayed as the intensity measure. For ChIP-seq, a 100 bp sliding window was used to scan the
genome. Read count in each window was shown at a 25 bp step size. E-box motifs CACGTG (black) and CANNTG (red) were mapped to peak regions
and are also shown. (C) ChIP-chip [34] and ChIP-seq [40] binding signals in mouse ES cells.
doi:10.1371/journal.pone.0026057.g005
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(Figure 7A, correlation coefficient=0.47, p-value,0.001). A
small cluster of samples (red circles) enriched in Wilms tumor have
low MYC but high MCS for reasons unknown to us (possible
explanations include other transcriptional regulators, such as N-
Myc, that may activate the same set of genes, lab/batch effects in
the microarray experiments, or others). However, other than these
samples, the correlation between MYC and MCS are strikingly
strong given the heterogeneity of the samples involved in the
analysis. Interestingly, when we evaluated the expression of the
MCS with that of RXRa, a transcription factor that drives
differentiation [45], we observe an inverse correlation (Figure 7B).
The use of the MCS to scan the large collection of microarray
samples representing both normal and cancer cells and tissues
provides a unique opportunity to survey the various cellular
contexts, in which Myc regulation of the MCS is active. In
addition to B cell lymphoma, we identified other cell types having
elevated expression of both MYC and MCS and found that 95.9%
(236/246) of these are various types of tumors, while only 57.7%
(4690/8129) of the total samples are tumors (Figure 7C, D). All
cell types shown in Figure 7C have statistically significant
fractions of samples (FDR,5%) that display both high MYC and
MCS expression when compared to randomly selected samples.
Among the identified tumors with high MYC and MCS expression,
several including acute lymphoblastic leukemia have been
associated with high MYC expression. For some tumors (e.g.
Ewing Sarcoma), the functional role of MYC pathway has not yet
been established.
The correlation between MYC and MCS in this very large
collection of gene expression profiles from diverse cells and tissues
underscores the importance of this cell type independent core set
of Myc target genes. Furthermore, this analysis provides the first
comprehensive microarray data-driven survey of cellular contexts
in which MYC might play an important role in regulating genes
involved in ribosome biogenesis.
Discussion
Regulation of the MCS genes involved in nucleolar
function and ribosomal biogenesis reveals Myc’s
primordial function
Our comprehensive analysis of genes directly regulated by Myc
reveals a cell type and species independent signature with
functions in ribosome biogenesis and nucleolar proteins involved
in RNA processing. This finding unifies many previous observa-
tions linking Myc to ribosome biogenesis in diverse mammalian
cell types and in Drosophila and underscores the importance of
nucleolar hypertrophy as a hallmark of cancer, which was
originally described in 1896 [23,27,28,29,30,46,47]. This hallmark
remains a distinctive feature of cancer cells, particularly for
Figure 6. Myc core target gene signature increases with the neoplastic switch to frank lymphoma in vivo. (A) Heatmap showing
expression levels of the 51 Myc core target genes in wild-type, pre-malignant Em-Myc (4–6 week old) littermates and of Em-Myc lymphoma. (B)
Clustering of human molecular Burkitt’s lymphoma (mBL) and non-mBL samples using the 51 core target genes. (C) and (D) Heatmaps showing
expression levels of B cell restricted (C) or ES cell restricted (D) upregulated Myc target genes in the mouse B cell samples. Green – low expression;
Red – high expression.
doi:10.1371/journal.pone.0026057.g006
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number of genes and gene sets related to ribosome biogenesis and
nucleolar function in human prostate cancer cells, and that
fibrillarin, which is one of 51 MCS genes, is necessary for prostate
cancer cell proliferation [48]. Fibrillarin levels correlate with Myc
levels in both the human prostate cancer precursor lesions, high
grade prostatic intraepithelial neoplasia (PIN), and in various
stages of human prostate cancer. This correlation provides a
molecular underpinning for increased nucleolar hypertrophy that
occurs during all phases of prostatic neoplasia [49].
The functional role of ribosomal biogenesis in Myc-mediated
tumorigenesis has been established through the effects of Rpl24
heterozygosity on Em-Myc lymphomagenesis [25,50], where Em-
Myc;Rpl24
+/2 mice have reduced spleen sizes, delayed lymphoma
development and prolonged survival compared to their Em-
Myc;Rpl24
+/+ littermates. Thus, normal ribosomal biogenesis is
essential for efficient tumorigenesis.
The overall function of the MCS suggests a primordial function
for Myc during evolution. Drosophila dMyc hypomorphs have
phenotypes of loss of ribosomal function, resulting in small cell and
body size [26]. Intriguingly, Myc was recently found to be
expressed in the interstitial stem cells of Hydra, an ancient marine
metazoan that has existed for over 600 million years [51]. Because
interstitial stem cells participate in regeneration of the Hydra
polyp and Myc is highly localized to the Hydra stem cell
compartment, Myc is likely to be central to tissue regeneration in
this organism. We expect that the primordial function of Myc in
ribosome biogenesis can also be found in Hydra through a
homologous Myc target gene signature.
Target gene context and cell type specificity
An early study, focused on the transcriptional circuitry of Oct4,
Sox2 and Nanog in hESCs, found that these three transcription
factors (TFs) co-occupy a substantial portion of their target genes
[52]. The data also indicated that these TFs collaborate to form
regulatory circuits consisting of autoregulatory and feed-forward
loops. More recently, transcriptional regulation has been assessed
in mouse ES cells by examining the promoters bound by nine TFs
Figure 7. Correlation of MYC and Myc core target gene signature (MCS) expression among 8129 samples. (A) Correlation plot of MCS
versus MYC expression across 8129 samples on the Affymetrix human U133A platform. Correlation coefficient=0.47. p-value was determined based
on correlation between MYC and randomly chosen genes (see Methods S1). Samples from a few cell or tissue types exhibiting patterns of interest
are highlighted in color. (B) Correlation plot of MCS versus RXRA expression across 8129 samples on the Affymetrix U133A platform. (C) Total
percentage and samples counts of each significantly enriched (FDR,5%) high MYC high MCS cell or tissue type in MYC+ MCS+ samples compared to
in all samples. (D) Comparison of total percentage of tumor samples in all of the data (57.7%) to the total percentage of MYC+ MCS+ samples that are
tumors (95.9%).
doi:10.1371/journal.pone.0026057.g007
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TFs and two transcriptional regulators using ChIP-seq [40].
Interestingly, these studies revealed that target gene promoters
bound by only a few TFs are largely inactive or repressed while
those bound by four or more tend to be active in the pluripotent
state, and to be repressed upon differentiation. Even though both
of these extensive studies included Myc, they were conducted in
mESCs. Here we provide insight into MYC’s role in human stem
cells, where we have defined a stem cell specific set of Myc targets,
which include LIN28 and are found in both murine and human
ESCs and in iPSCs, but not in human P493-6 B lymphocytes.
Recently, the LIN28 family member LIN28B, whose expression
in highly elevated in a number of human tumors, was shown to be
a direct MYC target in P493-6 B cells and mouse lymphoma [53].
Lin28B inhibits the maturation of members of the Let7 family of
miRNAs that are predicted to repress MYC, completing an
intricate autoregulatory loop important in both stem biology and
tumorigenesis. It is intriguing to note that the three factors, Sox2,
Oct4, and Klf4, can be complemented by either MYC or LIN28 to
induce more efficiently pluripotency in fibroblasts [54,55]. As
such, the role of Myc and LIN28 in the regulation of miRNAs,
which are not determined in the current study, is also expected to
play critical roles in the pluripotent stem cell state.
Our study also defined Myc target genes that are bound and
regulated only in B cells and not in ESCs. The expression of B cell-
specific Myc targets correlated well with in vivo expression of these
genes in Em-Myc malignant lymphocytes as compared to the
normal or pre-malignant counterparts. These observations
indicate that our identification of B-cell specific genes in the
human P493-6 model is relevant to Myc-driven lymphomagenesis,
whereas ESC-specific genes do not appear to be relevant to in vivo
lymphoma.
Most importantly, our comprehensive analysis of genome-wide
ChIP-chip, ChIP-seq and gene expression data from multiple cell
types allowed us to define a stringent set of cell type and species
independent MYC core target genes. The expression of the MCS
which is shared amongst six murine or human cell systems
increased from normal to premalignant to neoplastic B cells. The
fact that the expression of the 51 core set of Myc targets also
correlates with MYC expression amongst 8129 gene expression
profiles from diverse normal and diseased human cells and tissues
underscores the cell type independent nature of this set. Among
the tumors with high MYC and MCS expression, several including
acute lymphoblastic leukemia have been associated with high MYC
expression, whereas this association was not previously known for
tumors like Ewing Sarcoma. Thus, this analysis opens up new
biological avenues to investigate. The signature of this core 51
gene set is dominated by genes involved in ribosome biogenesis
and RNA processing, revealing that Myc induces biomass
accumulation in a cell type-independent fashion. In this regard,
deregulated expression of MYC in cancers could cause constitutive
biomass accumulation, rendering cancer cells addicted to nutrients
such as glucose or glutamine similar to yeast mutants that were
genetically engineered to have constitutive ribosome biogenesis
[56,57,58].
Materials and Methods
Additional experimental procedures are documented as Meth-
ods S1.
P493-6 cell culture
P493-6 cells, originally established in [31], were cultured in
RPMI with 10% fetal bovine serum and penicillin and
streptomycin and treated with tetracycline (0.1 mg/ml) to silence
exogenous MYC transgene expression as previously described
[21,32].
Human ES cell culture and trophoblast cell differentiation
The H9 hES cells were purchased from the WiCell Research
Institute and were initially cultured on PMEFs as instructed by the
provider. H9 cells used in this experiment were at passage 30 and
were karyotypically normal at the beginning of the experiment.
Differentiation of hESC in the presence of BMP4 was
performed as previously described [38].
Flow cytometric analysis
Trophoblast cells were dissociated with trypsin, fixed with 2%
paraformaldehyde (fresh prepared), permeabilized with 0.1%triton
X 100, blocked with 4% c globulins, and stained with monoclonal
antibody Cytokeratin 7 (Dako) as primary antibody and PE- anti
mouse IgG1 (BD) as secondary antibody. Flow cytometric analysis
was performed on a FACSCalibur instrument using the CellQuest
software (BD Bioscience, San Jose, CA). At least 10,000 events
were acquired for each sample.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed on
untreated P493-6 cells as previously described [21]. For H9 hESCs,
the cells were treated with formaldehyde (1% final concentration) for
10 min on the plate. Chromatin from 10
7 cells was incubated with
1 ug antibody. Antibody-chromatin complexes were pulled down
with Staph A cells, washed, and formaldehyde crosslinks were
reversed as previously described [21]. Antibodies used for ChIP were
anti-MYC (Santa Cruz cat# sc-764, Epitomics rabbit monoclonal
cat# 1472-1), IgG control (normal rabbit IgG, Santa Cruz cat# sc-
2027). For ChIP-chip, 10% of the IP product from the MYC and IgG
control pulldowns was used for amplification following Affymetrix
ChIP-chip protocol. Amplified ChIP products were fragmented,
labeled and hybridized to Affymetrix 1.0 Human Promoter arrays.
RNA Extraction and Gene Expression Analysis
RNA was extracted from 1–5 million P493-6 (untreated and tet
treated) and H9 (untreated and BMP4 treated) cells using a
Qiagen RNeasy kit (cat# 74104). RNA samples were submitted to
the Johns Hopkins Microarray Core Facility to be hybridized to
Agilent Whole Human Genome 44K microarrays (H9 cells) or
Affymetrix Human Genome U133 Plus 2.0 or Human Exon 1.0
ST Arrays (P493-6 cells). One ug RNA was converted to cDNA
using the TaqMan Reverse Transcription Kit (Applied Biosys-
tems, cat# N808-0234). cDNA was amplified using 250 nM gene
specific primers and Power SYBR Green (Applied Biosystems,
cat# 4367659). MYC and B-ACTIN was amplified using Taqman
gene expression assays. Quantitation was performed using a
relative standard curve. Expression level for each gene was
normalized to B-ACTIN. PCR primer sequences are provided in
Table S4.
Data Analysis
Detailed data analysis methods and methods for derivation of
the different sets of Myc targets are provided in Methods S1.
ChIP-chip and ChIP-seq Data Analysis. All ChIP-chip
data (including human P493 B cell and H9 ES cell, and mouse ES
cell data) were analyzed using CisGenome [33]. Details are
provided in Methods S1.
Gene Expression Data Analysis. Affymetrix Exon array
data (including nuclear run-on, total RNA and all RNA in human
Myc Core Target Gene Signature
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RMA was used for processing of other microarray data. Details
are provided in Methods S1.
Myc Targets in Human P493-6 B Cells and Human H9 ES
Cells. Details for deriving common and cell type restricted Myc
targets are provided in Methods S1.
Analysis of 8129 GEO Microarray Samples. 8129
Affymetrix Human U133A microarray samples were collected
from GEO [60]. The samples were normalized and processed
using fRMA [61] to compute gene expression levels. Details are
provided in Methods S1.
Data Availability
All new microarray and ChIP-chip data generated by this study
are submitted to Gene Expression Omnibus (GEO). GEO
accession numbers: GSE32220, GSE32239.
Supporting Information
Figure S1 Expression of 43 Myc core signature genes in
fibroblasts, human induced pluripotent stem cells
(iPSC) or human embryonic cells (ESC). The data were
obtained from http://amazonia.transcriptome.eu/. Each vertical
colored bar represents a single sample and the height corresponds
to expression level of the indicated Affymetrix probe set.
(PDF)
Figure S2 GSEA summary statistics of Ribosome path-
way gene set demonstrate its significant enrichment
(FDR=0.26%) in premalignant Em-Myc B220+ samples
as compared to wild type. Profile of the Running Enrichment
Score (ES) and position of gene set members on the rank ordered
list show positive correlation with premalignant Em-Myc B220+
data.
(PDF)
Figure S3 Unsupervised clustering of lymphoma sam-
ples with the 51 gene Myc core signature. Note the
clustering of all 44 molecular Burkitt lymphoma (mBL) samples
together with 10 non-mBL samples. The remaining non-mBL
samples cluster in a separate branch.
(PDF)
Figure S4 Clustering of downregulated B-cell restricted
or embryonic stem (ES) cell restricted Myc target genes
among mouse samples from wild-type (WT), premalig-
nant (Pre) or frankly malignant (Tumor) B220+ lympho-
cytes.
(PDF)
Table S1 ChIP-chip, ChIP-seq and gene expression data
used in the analysis.
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